Xeris Biopharma will present new and updated data on ready-to-use glucagon, Cushing’s syndrome treatment and a once-weekly levothyroxine candidate at three US medical meetings this autumn.
Xeris Biopharma Holdings said it will present new and updated data on three of its endocrinology programmes at meetings in the US this autumn, including material on its commercial products Gvoke and Recorlev, as well as its pipeline candidate XP-8121 for hypothyroidism. The company said the presentations are scheduled for the Breakthrough T1D Clinical & Research Congress, the Cardiometabolic Health Congress and the American Thyroid Association annual meeting. The programme suggests Xeris is using the conference season to reinforce its position in rare disease and hormone-related care while continuing to press its case for future growth.
According to the company, one of the main presentations focuses on severe hypoglycaemia and whether clinicians who know the guidelines are actually prescribing ready-to-use glucagon in line with them. Xeris said the analysis highlights a gap between awareness and prescribing behaviour for Gvoke, which is approved for severe low blood sugar in people with diabetes aged two and above. That message builds on earlier company claims that demand for ready-to-use glucagon remains significant; in 2023, Xeris said it had shipped more than one million units of Gvoke and cited diabetes guidance suggesting millions of patients could benefit from carrying such products.
Xeris also plans to showcase a case study involving Recorlev, its levoketoconazole treatment for endogenous hypercortisolaemia in adults with Cushing’s syndrome when surgery is not an option or has not worked. The company said the case involved a patient with difficult-to-control type 2 diabetes and hypertension, and that cortisol normalisation was accompanied by improvements in several cardiometabolic measures. Separately, it will present a TriNetX analysis on hypothyroidism using linked levothyroxine and thyroid-stimulating hormone data, which Xeris described as its first public look at that real-world dataset. The company has previously said XP-8121, an investigational once-weekly subcutaneous levothyroxine formulation, remains one of its lead development programmes.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
